TY - JOUR
T1 - Electrolyzed-reduced water reduced hemodialysis-induced erythrocyte impairment in end-stage renal disease patients
AU - Huang, K. C.
AU - Yang, C. C.
AU - Hsu, S. P.
AU - Lee, K. T.
AU - Liu, H. W.
AU - Morisawa, S.
AU - Otsubo, K.
AU - Chien, C. T.
N1 - Funding Information:
This work was supported by the National Science Council of the Republic of China (NSC 92-2320-B002-078), National Taiwan University Hospital (NTUH94S104), Taipei City United Hospital Heping Branch, and Formosan Blood Purification Foundation.
PY - 2006/7/7
Y1 - 2006/7/7
N2 - Chronic hemodialysis (HD) patients increase erythrocyte susceptibility to hemolysis and impair cell survival. We explored whether electrolyte-reduced water (ERW) could palliate HD-evoked erythrocyte impairment and anemia. Forty-three patients undergoing chronic HD were enrolled and received ERW administration for 6 month. We evaluated oxidative stress in blood and plasma, erythrocyte methemoglobin (metHb)/ferricyanide reductase activity, plasma metHb, and proinflammatory cytokines in the chronic HD patients without treatment (n = 15) or with vitamin C (VC)- (n = 15), vitamin E (VE)-coated dialyzer (n = 15), or ERW treatment (n = 15) during an HD course. The patients showed marked increases (15-fold) in blood reactive oxygen species, mostly H2O 2, after HD without any treatment. HD resulted in decreased plasma VC, total antioxidant status, and erythrocyte metHb/ferricyanide reductase activity and increased erythrocyte levels of phosphatidylcholine hydroperoxide (PCOOH) and plasma metHb. Antioxidants treatment significantly palliated single HD course-induced oxidative stress, plasma and RBC PCOOH, and plasma metHb levels, and preserved erythrocyte metHb /ferricyanide reductase activity in an order VC> ERW> VE-coated dialyzer. However, ERW had no side effects of oxalate accumulation easily induced by VC. Six-month ERW treatment increased hematocrit and attenuated proinflammatory cytokines profile in the HD patients. In conclusion, ERW treatment administration is effective in palliating HD-evoked oxidative stress, as indicated by lipid peroxidation, hemolysis, and overexpression of proinflammatory cytokines in HD patients.
AB - Chronic hemodialysis (HD) patients increase erythrocyte susceptibility to hemolysis and impair cell survival. We explored whether electrolyte-reduced water (ERW) could palliate HD-evoked erythrocyte impairment and anemia. Forty-three patients undergoing chronic HD were enrolled and received ERW administration for 6 month. We evaluated oxidative stress in blood and plasma, erythrocyte methemoglobin (metHb)/ferricyanide reductase activity, plasma metHb, and proinflammatory cytokines in the chronic HD patients without treatment (n = 15) or with vitamin C (VC)- (n = 15), vitamin E (VE)-coated dialyzer (n = 15), or ERW treatment (n = 15) during an HD course. The patients showed marked increases (15-fold) in blood reactive oxygen species, mostly H2O 2, after HD without any treatment. HD resulted in decreased plasma VC, total antioxidant status, and erythrocyte metHb/ferricyanide reductase activity and increased erythrocyte levels of phosphatidylcholine hydroperoxide (PCOOH) and plasma metHb. Antioxidants treatment significantly palliated single HD course-induced oxidative stress, plasma and RBC PCOOH, and plasma metHb levels, and preserved erythrocyte metHb /ferricyanide reductase activity in an order VC> ERW> VE-coated dialyzer. However, ERW had no side effects of oxalate accumulation easily induced by VC. Six-month ERW treatment increased hematocrit and attenuated proinflammatory cytokines profile in the HD patients. In conclusion, ERW treatment administration is effective in palliating HD-evoked oxidative stress, as indicated by lipid peroxidation, hemolysis, and overexpression of proinflammatory cytokines in HD patients.
KW - Electrolyzed-reduced water
KW - Hemodialysis
KW - Hemolysis
KW - Oxidative stress
UR - http://www.scopus.com/inward/record.url?scp=33746132354&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746132354&partnerID=8YFLogxK
U2 - 10.1038/sj.ki.5001576
DO - 10.1038/sj.ki.5001576
M3 - Article
C2 - 16760903
AN - SCOPUS:33746132354
SN - 0085-2538
VL - 70
SP - 391
EP - 398
JO - Kidney International
JF - Kidney International
IS - 2
ER -